Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.
作者信息
Jones Jocelyn D, Jackson Sylvia H, Agboton Carmen, Martin Tonya S
出版信息
P T. 2011 Oct;36(10):634-40.
Abstract
摘要
相似文献
1
Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.阿齐沙坦美索米酯（依达比）：第八种血管紧张素II受体阻滞剂。
P T. 2011 Oct;36(10):634-40.
2
Azilsartan medoxomil (Edarbi) the eighth ARB.阿齐沙坦美索米酯（依达比），第八种血管紧张素Ⅱ受体拮抗剂。
Med Lett Drugs Ther. 2011 May 16;53(1364):39-40.
3
Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.奥美沙坦酯：一种用于治疗高血压的新型血管紧张素 II 受体拮抗剂。
Ann Pharmacother. 2011 Dec;45(12):1506-15. doi: 10.1345/aph.1Q468. Epub 2011 Nov 24.
4
Azilsartan medoxomil: a review of its use in hypertension.奥美沙坦酯：在高血压治疗中的应用评价。
Clin Drug Investig. 2012 Sep 1;32(9):621-39. doi: 10.2165/11209600-000000000-00000.
5
Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.新型强效及长效血管紧张素 II 型 1 型受体阻滞剂阿齐沙坦酯在大鼠和犬模型中的降压、胰岛素增敏和肾脏保护作用。
Eur J Pharmacol. 2011 Nov 1;669(1-3):84-93. doi: 10.1016/j.ejphar.2011.07.014. Epub 2011 Jul 28.
6
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.在 1 期和 2 期高血压患者中，血管紧张素受体阻断剂阿齐沙坦酯与奥美沙坦和缬沙坦对动态血压和诊室血压的影响。
Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31.
7
Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.奥美沙坦酯/氢氯噻嗪：一种新型的固定剂量复方降压药。
Ann Pharmacother. 2013 May;47(5):694-703. doi: 10.1345/aph.1R618. Epub 2013 Apr 12.
8
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.奥美沙坦酯氨氯地平复方制剂降压疗效优于奥美沙坦酯氢氯噻嗪复方制剂治疗 2 级收缩期高血压。
Hypertension. 2012 Aug;60(2):310-8. doi: 10.1161/HYPERTENSIONAHA.111.188284. Epub 2012 Jun 18.
9
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?奥美沙坦酯治疗高血压：最终的血管紧张素受体阻滞剂？
Expert Opin Pharmacother. 2013 Nov;14(16):2249-61. doi: 10.1517/14656566.2013.834887. Epub 2013 Sep 26.
10
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.氢氯噻嗪与氯噻酮联合奥美沙坦酯的降压疗效。
Am J Med. 2012 Dec;125(12):1229.e1-1229.e10. doi: 10.1016/j.amjmed.2012.05.023. Epub 2012 Aug 30.
引用本文的文献
1
Angiotensin Receptor Blockers and the Risk of Suspected Drug-Induced Liver Injury: A Retrospective Cohort Study Using Electronic Health Record-Based Common Data Model in South Korea.血管紧张素受体阻滞剂与疑似药物性肝损伤风险：韩国基于电子健康记录通用数据模型的回顾性队列研究。
Drug Saf. 2024 Jul;47(7):673-686. doi: 10.1007/s40264-024-01418-4. Epub 2024 Mar 21.
2
Effect of Azilsartan on clinical blood pressure reduction compared to other angiotensin receptor blockers: a systematic review and meta-analysis.与其他血管紧张素受体阻滞剂相比，阿齐沙坦降低临床血压的效果：一项系统评价和荟萃分析。
Ann Med Surg (Lond). 2023 Dec 8;86(2):958-967. doi: 10.1097/MS9.0000000000001547. eCollection 2024 Feb.
3
Role of G-protein coupled receptors in cardiovascular diseases.G蛋白偶联受体在心血管疾病中的作用。
Front Cardiovasc Med. 2023 Jun 5;10:1130312. doi: 10.3389/fcvm.2023.1130312. eCollection 2023.
4
Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation.中心复合设计制备阿齐沙坦美洛昔酯纳米乳以改善其水溶性和肠道渗透性：体外和离体评价
Pharmaceuticals (Basel). 2022 Oct 29;15(11):1343. doi: 10.3390/ph15111343.
5
Fimasartan: A new armament to fight hypertension.法米沙坦：对抗高血压的新武器。
J Family Med Prim Care. 2019 Jul;8(7):2184-2188. doi: 10.4103/jfmpc.jfmpc_300_19.
6
Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.血管紧张素II受体拮抗剂阿齐沙坦美洛昔酯在轻度至中度肝损伤患者中药代动力学及安全性的单中心评估
J Clin Pharmacol. 2018 Jan;58(1):48-56. doi: 10.1002/jcph.970. Epub 2017 Jul 27.
7
The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.阿齐沙坦美洛昔酯治疗（胶囊剂型），剂量范围为10至80毫克：显著、快速降低临床舒张压和收缩压。
J Clin Hypertens (Greenwich). 2017 Mar;19(3):312-321. doi: 10.1111/jch.12895. Epub 2016 Aug 25.
8
Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.阿齐沙坦与ACE抑制剂在抗高血压治疗中的比较：观察性EARLY注册研究的一年结果
BMC Cardiovasc Disord. 2016 Mar 8;16:56. doi: 10.1186/s12872-016-0222-6.
9
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.在临床试验与常规实践中比较肾素-血管紧张素受体阻滞剂阿齐沙坦美洛昔酯与血管紧张素转换酶抑制剂雷米普利：来自前瞻性EARLY注册研究的见解
Trials. 2015 Dec 19;16:581. doi: 10.1186/s13063-015-1100-8.
10
EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry.与血管紧张素转换酶抑制剂相比，早期使用阿齐沙坦进行抗高血压治疗——EARLY 高血压登记研究的原理和设计。
BMC Cardiovasc Disord. 2013 Jul 2;13:46. doi: 10.1186/1471-2261-13-46.
本文引用的文献
1
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.血管紧张素受体阻断剂阿齐沙坦酯与血管紧张素转换酶抑制剂雷米普利的降压疗效比较。
J Hum Hypertens. 2013 Aug;27(8):479-86. doi: 10.1038/jhh.2013.6. Epub 2013 Mar 21.
2
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.采用动态血压监测比较新型血管紧张素Ⅱ受体拮抗剂阿齐沙坦酯与缬沙坦。
J Clin Hypertens (Greenwich). 2011 Jul;13(7):467-72. doi: 10.1111/j.1751-7176.2011.00482.x. Epub 2011 Jun 20.
3
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.在 1 期和 2 期高血压患者中，血管紧张素受体阻断剂阿齐沙坦酯与奥美沙坦和缬沙坦对动态血压和诊室血压的影响。
Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31.
4
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.阿齐沙坦酯和美托洛尔对动态和诊室血压的比较影响。
J Clin Hypertens (Greenwich). 2011 Feb;13(2):81-8. doi: 10.1111/j.1751-7176.2010.00425.x.
5
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.预测美国心血管疾病的未来：美国心脏协会的政策声明。
Circulation. 2011 Mar 1;123(8):933-44. doi: 10.1161/CIR.0b013e31820a55f5. Epub 2011 Jan 24.
6
Deaths preventable in the U.S. by improvements in use of clinical preventive services.美国可以通过改善临床预防服务的使用来预防死亡。
Am J Prev Med. 2010 Jun;38(6):600-9. doi: 10.1016/j.amepre.2010.02.016.
7
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.美国国家高血压预防、检测、评估与治疗联合委员会第七次报告：JNC 7报告。
JAMA. 2003 May 21;289(19):2560-72. doi: 10.1001/jama.289.19.2560. Epub 2003 May 14.
Zotero 插件